Topic: neurodegenerative diseases
Octave Biosciences picked up a pair of industry veterans for its board of directors, as well as $14 million to advance its care management technology.
Orion Pharma is pressing ahead with a pivotal trial for its amyotrophic lateral sclerosis drug ODM-109, despite mixed results in a phase 2 trial.
Appello Pharmaceuticals raised $10.5 million to fund its glutamate-modulating Parkinson’s disease treatment licensed from Vanderbilt University.
AbbVie and Calico reupped their $1.5 billion collaboration on age-related diseases, with a new billion-dollar commitment split between the two.
The Dementia Discovery Fund capped its fundraising at $350 million; it was nudged across the line by a $60 million investment from AARP.
Nodthera raised £28 million in series A funding to develop NLRP3 inflammasome inhibitors for chronic inflammation.
A "multi-omic" analysis of more than 900 donor brains linked the amount of herpes virus in a person's brain to the presence of Alzheimer's markers.
Alzheimer’s startup Cortexyme rounded up $76 million for a potentially first-in-class antibiotic treatment, while others struggle in the field.
Denali will acquire the rights to bispecific antibodies targeting the blood-brain barrier that were developed under its collaboration with F-star.
Johnson & Johnson unit Janssen joins the Alzheimer's failure club after deciding to stop trials of its BACE inhibitor atabacestat.